Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blind randomized CLL12 trial. (1938)
Petra Langerbeins
2019 Presentations Access
Thank you for your interest in viewing the iwCLL 2019 video presentations.
Please complete the following information below to access the presentations.
